Skip to main content

Month: December 2020

FDA Accepts Protocol for Adding an Open-Label Extension to CytoDyn’s Phase 3 Trial for Severe-to-Critical COVID-19 Patients

The agency also provided specific guidance for inclusion/exclusion criteria for patients seeking leronlimab under eIND authorizationVANCOUVER, Washington, Dec. 30, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the U.S. Food and Drug Administration (“FDA”) has accepted the protocol submitted on December 28 for adding an open-label extension to its Phase 3 trial (“CD12”). Hospitals previously participating in the CD12 trial now have the option of enrolling additional eligible patients, with all patients receiving leronlimab. Treatment for eligible patients will continue until further notified by the FDA and/or CytoDyn.The...

Continue reading

Kaixin Auto Holdings Announces Unaudited First Half 2020 Financial Results

BEIJING, Dec. 30, 2020 (GLOBE NEWSWIRE) — Kaixin Auto Holdings (“Kaixin” or the “Company”) (NASDAQ: KXIN), one of the premium used car dealership networks in China, today announced its unaudited financial results for the six months ended June 30, 2020.First Half of 2020 Operational HighlightsGross Merchandise Value (GMV)1 was US$34.2 million, representing a decrease of 84.5% from US$220.8 million in the first half of 2019.Number of cars sold was 673 units, compared with 3,657 units sold in the first half of 2019.Inventory turnover days were 98 days, compared with 41 days in the first half of 2019.First Half of 2020 Financial HighlightsTotal net revenues were US$33.3 million, representing a decrease of 83.7% from US$204.6 million in the first half of 2019.Gross profit was US$0.9 million, representing a decrease...

Continue reading

Histogen Announces Pricing of $14.0 Million Upsized Public Offering

SAN DIEGO, Dec. 30, 2020 (GLOBE NEWSWIRE) — Histogen Inc. (Nasdaq: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that it has it has priced a public offering of an aggregate of 14,000,000 shares of common stock (or common stock equivalents offered through the issuance of pre-funded warrants), together with accompanying warrants to purchase up to an aggregate of 14,000,000 shares of common stock, at an effective public offering price of $1.00 per share and accompanying warrant. Each share of common stock (or common stock equivalent offered through the issuance of a pre-funded warrant) will be sold in the offering with one warrant to purchase one share of common stock....

Continue reading

CEMATRIX Grants Incentive Options to Executive Officer

CALGARY, Alberta, Dec. 30, 2020 (GLOBE NEWSWIRE) — CEMATRIX Corporation (TSXV: CVX) (the “Corporation”) granted incentive stock options to an Executive Officer of the Corporation, pursuant to the Corporation’s Stock Option Plan, on December 29, 2020 for the purchase of a total of 250,000 common shares at an exercise price of $0.59 per share, at any time up to and including December 29, 2025.ABOUT CEMATRIXCEMATRIX is a rapidly growing, cash flow positive company that manufactures and supplies technologically advanced cellular concrete products developed from proprietary formulations across North America. This unique cement-based material with superior thermal protection delivers cost-effective, innovative solutions to a broad range of problems facing the infrastructure, industrial (including oil and gas) and commercial markets. Through...

Continue reading

MedMira Announces Product Update

HALIFAX, Nova Scotia, Dec. 30, 2020 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR), is pleased to announce its validated REVEALCOVID-19TMPLUS Total Antibody Test for the detection of total antibodies against both the Nucleocapsid and Spike regions of the SARS-CoV-2. REVEALCOVID-19TMPLUS Total Antibody Test is an update to MedMira’s REVEALCOVID-19TMTotal Antibody Test that addresses the total antibody testing demands arising from recent developments in COVID-19 vaccines across global markets.The two vaccines from Pfizer and Moderna, which were recently authorized for use in the United States and Canada, generate neutralizing antibodies against the Spike protein of the SARS-CoV-2 virus in order to provide the necessary protection of vaccinated individuals. The discovery of at least two new mutations of the SARS-CoV-2...

Continue reading

RLH Corporation Announces Agreement to be Acquired by Sonesta International Hotels for $3.50 Per Share in Cash; Transaction Valued at Approximately $90 Million

DENVER, Dec. 30, 2020 (GLOBE NEWSWIRE) — RLH Corporation (NYSE: RLH) (“RLH” or “Red Lion”), the 10th-largest US-based hotel franchise company serving a large segment of American consumers, today announced that it has entered into a definitive merger agreement (“Merger Agreement” or “agreement”) with Sonesta International Hotels Corporation (“Sonesta”) under which RLH will be acquired by Sonesta in an all-cash transaction valued at approximately $90 million. The agreement has been unanimously approved by the RLH Board of Directors.Under the terms of the Merger Agreement, holders of RLH’s common stock will receive $3.50 per share in cash. This represents an 88% premium over the November 4, 2020, closing share price, the last trading date before Red Lion most recently provided an update on its strategic alternatives, and a 30% premium...

Continue reading

Independence Gold Announces Closing of Oversubscribed $2,150,000 Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATESVANCOUVER, British Columbia, Dec. 30, 2020 (GLOBE NEWSWIRE) — Independence Gold Corp. (TSX.V: IGO) (the “Company”) wishes to announce that it has closed a second and final tranche of the non-brokered private placement announced on December 8, 2020 (the “Offering”).The Company issued 4,285,714 units (the “Units”) at a price of $0.14 per Unit for proceeds of $599,999.96 (the “Unit Proceeds”), and 4,687,500 flow-through common shares (“FT Common Shares”), and together with the Units, the “Securities”) at a price of $0.16 per FT Common Share for proceeds of $750,000 (together with the Unit Proceeds, the “Funds”). Including the first tranche of the Offering (the “First Tranche”) announced on December 21, 2020 (the “First Tranche...

Continue reading

Cardinal Energy Ltd. Announces Closing of Private Placement

CALGARY, Alberta, Dec. 30, 2020 (GLOBE NEWSWIRE) — Cardinal Energy Ltd. (“Cardinal” or the “Company“) (TSX: CJ) announces that it has closed the non-brokered private placement (the “Private Placement“) of 2nd lien secured notes for gross proceeds of $16,244,000 and 8,122,000 units (the “Units“) at a subscription price of $0.50 per Unit for proceeds of $4,061,000 as announced on December 2, 2020. The proceeds from the Private Placement will be used to repay Cardinal’s outstanding 5.50% convertible subordinated debentures which are maturing on December 31, 2020 and for general corporate purposes.As a condition of the financing, certain directors participated in the Private Placement for approximately 23% of the offering. Cardinal insiders currently own approximately 26% of the...

Continue reading

Focus Graphite Announces Closing of $1,150,000 Private Placement

KINGSTON, Ontario, Dec. 30, 2020 (GLOBE NEWSWIRE) — Focus Graphite Inc. (TSXV: FMS) (the “Company” or “Focus Graphite”) is pleased to announce it has closed its previously announced non-brokered private placement (the “Offering”) for total gross proceeds of $1,150,000. The closing of the Offering occurred in two final tranches of $500,000 (the “Second Tranche”) and $300,000 (the “Final Tranche”) respectively subsequent to the previously announced first tranche closing of December 18, 2020.As part of the Second Tranche, the Company issued 10,000,000 units (the “Flow-Through Units”) at a price of $0.05 per Unit. Each Unit is comprised of one (1) flow-through common share and one common share purchase warrant (a “Warrant”). Each Warrant entitles its holder to purchase one (1) common share at a price of $0.055...

Continue reading

Eloro Resources Announces Filing of Final Short Form Prospectus and Exercise of Over-Allotment Option by Underwriters

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY, OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES.TORONTO, Dec. 30, 2020 (GLOBE NEWSWIRE) — Eloro Resources Ltd. (the “Company” or “Eloro”) (TSX-V: ELO; OTCQX: ELRRF; FSE: P2QM) is pleased to announce that, in connection with its previously announced bought deal financing (the “Financing”) (see Eloro press releases dated December 16, 2020 and December 9, 2020), it has filed a final short form prospectus with the applicable securities regulators in each of the provinces of Canada, except Quebec. Under the terms of the Financing, Haywood Securities Inc., as lead underwriter, and Echelon Wealth Partners Inc. (the “Underwriters”) agreed to purchase, on a bought deal basis, 3,548,400 units (the “Units”) at...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.